

RISE by the Numbers

As of October 2022

The U.S. Agency for International Development's Reaching Impact, Saturation, and Epidemic Control (RISE) program assists countries to respond to the HIV and COVID-19 pandemics, providing technical assistance, service delivery, research, and cross-cutting health system support to address critical HIV and COVID-19 pandemic response priorities. All data shared are cumulative, unless otherwise noted.

RISE programming has addressed challenges in 22 countries:

- **HIV response** supported in 14 countries
- **COVID-19 response** supported in 15 countries
- **COVID-19 Test-to-Treat** programming strengthened in 5 countries
- **HIV technical assistance** provided in 8 countries
- Hosting HIV and/or HPV **prevention research studies** in 2 countries

HIV



69,825

people diagnosed with HIV through RISE testing services



95.8%

of clients testing positive linked to antiretroviral therapy (ART) services



156,133

people provided with lifesaving ART across 2 countries (Burundi and Nigeria in FY22)



95.8%

of clients on ART are virally suppressed (FY22)



28,084

RISE clients currently using pre-exposure prophylaxis



56,033

clients provided with voluntary medical male circumcision for HIV prevention

COVID



10,289,433

COVID-19 vaccines administered



14

PSA plants supported to generate oxygen



53,338

health workers trained on COVID-19 case management



16,470

health workers trained on COVID-19 related infection prevention and control and/ or water, sanitation and hygiene



16

national policies, protocols, or guidelines developed or adapted with U.S. Government and RISE support



This brief was made possible through the United States Agency for International Development-funded RISE program under the terms of the cooperative agreement 7200AA19CA00003. The contents are the responsibility of the RISE program and do not necessarily reflect the views of USAID or the United States Government.